SCHEMBL20134982

SCHEMBL20134982

Cc1cnc(N[C@@H]2CN(C(=O)c3ccc(C4(C(C)C)NC(=O)NC4=O)cc3)C[C@H]2O)c(C)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 4/20 0.35
HPGD P15428 1/20 0.33
PAK1 Q13153 1/20 0.32
MMP2 P08253 2/20 0.32
MMP9 P14780 1/20 0.32
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
KMT2A Q03164 1/20 0.31
KDM5A P29375 1/20 0.31
ADAMTS5 Q9UNA0 4/20 0.31
MMP14 P50281 1/20 0.31
CCNK O75909 1/20 0.31
CDK12 Q9NYV4 1/20 0.31
ADAM17 P78536 1/20 0.30
ALDH1A1 P00352 1/20 0.30
PDE2A O00408 1/20 0.30
TXK P42681 1/20 0.30
JAK3 P52333 1/20 0.30
BTK Q06187 1/20 0.30
ITK Q08881 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20134977 1.00 CRBN (0.35) CRBNHPGDPAK1MMP2MMP9
SCHEMBL20809252 0.91 PAK1 (0.37) CRBNHPGDPAK1MMP2MMP9
Hydrochloric Acid SCHEMBL20135392 0.90 PAK1 (0.36) CRBNHPGDPAK1MMP2MMP9
Hydrochloric Acid SCHEMBL20135389 0.90 PAK1 (0.36) CRBNHPGDPAK1MMP2MMP9
SCHEMBL20135263 0.86 PAK1 (0.46) CRBNPAK1MEN1KMT2ACCNK
SCHEMBL20135260 0.86 PAK1 (0.46) CRBNPAK1MEN1KMT2ACCNK
SCHEMBL20134879 0.86 CCNK (0.44) PAK1CCNKCDK12
SCHEMBL20134883 0.86 CCNK (0.44) PAK1CCNKCDK12
SCHEMBL20134945 0.86 CCNK (0.44) PAK1CCNKCDK12
SCHEMBL20135485 0.86 CCNK (0.44) PAK1CCNKCDK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 CRBN 3363/4885HPGD 74/4885PAK1 2256/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 CRBN 3419/4885HPGD 75/4885PAK1 2509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.